News & Updates
Filter by Specialty:
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
01 Jul 2024
KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.
KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
28 Jun 2024
En bloc resection significantly reduces NMIBC recurrence at 1 year
A multicentre, randomized, phase III trial conducted by researchers from the Chinese University of Hong Kong (CUHK) demonstrated a significant reduction in 1-year recurrence of non–muscle-invasive bladder cancer (NMIBC) with the use of en bloc vs standard resection (SR).
En bloc resection significantly reduces NMIBC recurrence at 1 year
25 Jun 2024
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
After 5 years of follow-up, median progression-free survival (PFS) has still not been reached in patients with advanced non-small-cell lung cancer (NSCLC) treated with lorlatinib in the phase III CROWN study, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumours.
